Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: Evaluation with FDG PET

Tatsuo Torizuka, Kenneth R. Zasadny, Paul V. Kison, Stephen G. Rommelfanger, Mark S. Kaminski, Richard L. Wahl

Research output: Contribution to journalArticle

Abstract

131I-anti-B1 (CD20) radioimmunotherapy (RIT) is a promising approach for treatment of non-Hodgkin's lymphoma (NHL). We assessed the tumor metabolic response to RIT using FDG PET. Methods: We examined 14 patients with NHL, who were given first a tracer dose of 131I-anti-B1 and then RIT, each preceded by infusion of unlabeled anti-B1. In 8 of 14 patients, PET was performed at baseline and 33-70 d after RIT. The other 6 patients underwent PET at baseline, 6-7 d after the tracer dose, and 5-7 d after RIT to estimate the early response to tracer dose and RIT. To assess tumor FDG uptake, standardized uptake value normalized for lean body mass (SUV-lean) was measured 1 h after FDG injection. Results: After RIT, complete response was observed in 6 patients, partial response in 6, and no response in 2. At 33-70 d after RIT, mean SUV-lean of 6 responders markedly declined to 41% of the baseline value (P <0.002). Soon after tracer dose and after RIT, mean SUV- lean of the other 6 responders decreased to 79% and 62% of the baseline values, respectively (P <0.05). In 2 nonresponders, SUV-lean did not significantly decline from the baseline value at 37 d after RIT. Conclusion: FDG PET metabolic data obtained 1-2 mo after RIT correlate well with the ultimate best response of NHL to RIT, more significantly than the early data after tracer dose or RIT. FDG uptake in NHL may decline gradually after RIT in responding patients.

Original languageEnglish (US)
Pages (from-to)999-1005
Number of pages7
JournalJournal of Nuclear Medicine
Volume41
Issue number6
StatePublished - Jun 2000
Externally publishedYes

Fingerprint

Radioimmunotherapy
Non-Hodgkin's Lymphoma
iodine-131 anti-B1 antibody

Keywords

  • FDG PET
  • Non-Hodgkin's lymphoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Torizuka, T., Zasadny, K. R., Kison, P. V., Rommelfanger, S. G., Kaminski, M. S., & Wahl, R. L. (2000). Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: Evaluation with FDG PET. Journal of Nuclear Medicine, 41(6), 999-1005.

Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy : Evaluation with FDG PET. / Torizuka, Tatsuo; Zasadny, Kenneth R.; Kison, Paul V.; Rommelfanger, Stephen G.; Kaminski, Mark S.; Wahl, Richard L.

In: Journal of Nuclear Medicine, Vol. 41, No. 6, 06.2000, p. 999-1005.

Research output: Contribution to journalArticle

Torizuka, T, Zasadny, KR, Kison, PV, Rommelfanger, SG, Kaminski, MS & Wahl, RL 2000, 'Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: Evaluation with FDG PET', Journal of Nuclear Medicine, vol. 41, no. 6, pp. 999-1005.
Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: Evaluation with FDG PET. Journal of Nuclear Medicine. 2000 Jun;41(6):999-1005.
Torizuka, Tatsuo ; Zasadny, Kenneth R. ; Kison, Paul V. ; Rommelfanger, Stephen G. ; Kaminski, Mark S. ; Wahl, Richard L. / Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy : Evaluation with FDG PET. In: Journal of Nuclear Medicine. 2000 ; Vol. 41, No. 6. pp. 999-1005.
@article{9b47babedce04f84acbe8a9c0b9b3d44,
title = "Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: Evaluation with FDG PET",
abstract = "131I-anti-B1 (CD20) radioimmunotherapy (RIT) is a promising approach for treatment of non-Hodgkin's lymphoma (NHL). We assessed the tumor metabolic response to RIT using FDG PET. Methods: We examined 14 patients with NHL, who were given first a tracer dose of 131I-anti-B1 and then RIT, each preceded by infusion of unlabeled anti-B1. In 8 of 14 patients, PET was performed at baseline and 33-70 d after RIT. The other 6 patients underwent PET at baseline, 6-7 d after the tracer dose, and 5-7 d after RIT to estimate the early response to tracer dose and RIT. To assess tumor FDG uptake, standardized uptake value normalized for lean body mass (SUV-lean) was measured 1 h after FDG injection. Results: After RIT, complete response was observed in 6 patients, partial response in 6, and no response in 2. At 33-70 d after RIT, mean SUV-lean of 6 responders markedly declined to 41{\%} of the baseline value (P <0.002). Soon after tracer dose and after RIT, mean SUV- lean of the other 6 responders decreased to 79{\%} and 62{\%} of the baseline values, respectively (P <0.05). In 2 nonresponders, SUV-lean did not significantly decline from the baseline value at 37 d after RIT. Conclusion: FDG PET metabolic data obtained 1-2 mo after RIT correlate well with the ultimate best response of NHL to RIT, more significantly than the early data after tracer dose or RIT. FDG uptake in NHL may decline gradually after RIT in responding patients.",
keywords = "FDG PET, Non-Hodgkin's lymphoma, Radioimmunotherapy",
author = "Tatsuo Torizuka and Zasadny, {Kenneth R.} and Kison, {Paul V.} and Rommelfanger, {Stephen G.} and Kaminski, {Mark S.} and Wahl, {Richard L.}",
year = "2000",
month = "6",
language = "English (US)",
volume = "41",
pages = "999--1005",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "6",

}

TY - JOUR

T1 - Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy

T2 - Evaluation with FDG PET

AU - Torizuka, Tatsuo

AU - Zasadny, Kenneth R.

AU - Kison, Paul V.

AU - Rommelfanger, Stephen G.

AU - Kaminski, Mark S.

AU - Wahl, Richard L.

PY - 2000/6

Y1 - 2000/6

N2 - 131I-anti-B1 (CD20) radioimmunotherapy (RIT) is a promising approach for treatment of non-Hodgkin's lymphoma (NHL). We assessed the tumor metabolic response to RIT using FDG PET. Methods: We examined 14 patients with NHL, who were given first a tracer dose of 131I-anti-B1 and then RIT, each preceded by infusion of unlabeled anti-B1. In 8 of 14 patients, PET was performed at baseline and 33-70 d after RIT. The other 6 patients underwent PET at baseline, 6-7 d after the tracer dose, and 5-7 d after RIT to estimate the early response to tracer dose and RIT. To assess tumor FDG uptake, standardized uptake value normalized for lean body mass (SUV-lean) was measured 1 h after FDG injection. Results: After RIT, complete response was observed in 6 patients, partial response in 6, and no response in 2. At 33-70 d after RIT, mean SUV-lean of 6 responders markedly declined to 41% of the baseline value (P <0.002). Soon after tracer dose and after RIT, mean SUV- lean of the other 6 responders decreased to 79% and 62% of the baseline values, respectively (P <0.05). In 2 nonresponders, SUV-lean did not significantly decline from the baseline value at 37 d after RIT. Conclusion: FDG PET metabolic data obtained 1-2 mo after RIT correlate well with the ultimate best response of NHL to RIT, more significantly than the early data after tracer dose or RIT. FDG uptake in NHL may decline gradually after RIT in responding patients.

AB - 131I-anti-B1 (CD20) radioimmunotherapy (RIT) is a promising approach for treatment of non-Hodgkin's lymphoma (NHL). We assessed the tumor metabolic response to RIT using FDG PET. Methods: We examined 14 patients with NHL, who were given first a tracer dose of 131I-anti-B1 and then RIT, each preceded by infusion of unlabeled anti-B1. In 8 of 14 patients, PET was performed at baseline and 33-70 d after RIT. The other 6 patients underwent PET at baseline, 6-7 d after the tracer dose, and 5-7 d after RIT to estimate the early response to tracer dose and RIT. To assess tumor FDG uptake, standardized uptake value normalized for lean body mass (SUV-lean) was measured 1 h after FDG injection. Results: After RIT, complete response was observed in 6 patients, partial response in 6, and no response in 2. At 33-70 d after RIT, mean SUV-lean of 6 responders markedly declined to 41% of the baseline value (P <0.002). Soon after tracer dose and after RIT, mean SUV- lean of the other 6 responders decreased to 79% and 62% of the baseline values, respectively (P <0.05). In 2 nonresponders, SUV-lean did not significantly decline from the baseline value at 37 d after RIT. Conclusion: FDG PET metabolic data obtained 1-2 mo after RIT correlate well with the ultimate best response of NHL to RIT, more significantly than the early data after tracer dose or RIT. FDG uptake in NHL may decline gradually after RIT in responding patients.

KW - FDG PET

KW - Non-Hodgkin's lymphoma

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0034084265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034084265&partnerID=8YFLogxK

M3 - Article

C2 - 10855624

AN - SCOPUS:0034084265

VL - 41

SP - 999

EP - 1005

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -